menu
    • menu

    Company profile for Cyteir Therapeutics

    NEW Drugs in Dev: 2
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cyteir is an innovator in DNA repair and synthetic lethality Cyteir’s scientists are leading the development of new gain-of-function synthetic lethal therapies. We have developed a unique and proprietary platform for the discovery and development of new synthetic lethal drugs. Cyteir’s scientists discovered the gain-of-function synthetic lethal relationship between AID-RAD51. We are leaders in the development of small mo...
    Cyteir is an innovator in DNA repair and synthetic lethality Cyteir’s scientists are leading the development of new gain-of-function synthetic lethal therapies. We have developed a unique and proprietary platform for the discovery and development of new synthetic lethal drugs. Cyteir’s scientists discovered the gain-of-function synthetic lethal relationship between AID-RAD51. We are leaders in the development of small molecules that target RAD51 for treatment of cancer and autoimmune diseases. We are developing new biomarkers of synthetic lethality, including AID

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cyteir TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    128 Spring St, Building A Suite 510, Lexington, MA 02421
    Telephone
    Telephone
    1.857.285.4140
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cyteir.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/cyteir-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/cyteirinfo?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
    Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

    07 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240307328830/en

    BUSINESSWIRE
    07 Mar 2024
    Share Share
    Ongoing Results From a Dose Expansion Cohort of CYT-0851
    Ongoing Results From a Dose Expansion Cohort of CYT-0851

    12 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231012887827/en

    BUSINESSWIRE
    12 Oct 2023
    Share Share
    Cyteir calls it quits after months of cost cutting
    Cyteir calls it quits after months of cost cutting

    30 Jun 2023

    // Max Bayer FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/cyteir-calls-it-quits-after-months-cost-cutting

    Max Bayer FIERCE BIOTECH
    30 Jun 2023
    Share Share
    Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program
    Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program

    30 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230630372398/en

    BUSINESSWIRE
    30 Jun 2023
    Share Share
    Preliminary Result with CYT-0851 in Advanced Solid Tumors Show Clinical Activity
    Preliminary Result with CYT-0851 in Advanced Solid Tumors Show Clinical Activity

    03 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230603005002/en

    BUSINESSWIRE
    03 Jun 2023
    Share Share
    Fusion and Cyteir refocus pipelines; Nona collaborating with PharmaEssentia
    Fusion and Cyteir refocus pipelines; Nona collaborating with PharmaEssentia

    12 May 2023

    // Tyler Patchen ENDPTS

    https://endpts.com/fusion-and-cyteir-refocus-pipelines-nona-biosciences-collaborating-with-pharmaessentia/

    Tyler Patchen ENDPTS
    12 May 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search